Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3233-3243

  Kim, Seon Kyu ^a   Roh, Yun Gil ^b   Park, Kiejung ^a   Kang, Tae Hong ^b   Kim, Wun Jae ^c   Lee, Ju Seog ^d   Leem, Sun Hee ^b   Chu, In Sun ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Dong A University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER CELL LINE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CCNB1 GENE; COHORT ANALYSIS; FEMALE; FOXM1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA MICROARRAY; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

CCNB1 PROTEIN, HUMAN; CYCLIN B1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELL PROLIFERATION; COHORT STUDIES; CYCLIN B1; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84902653623     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2761     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-53.
3. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001.
4. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
5. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 2008;113:710-6.
6. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6. (Pubitemid 36068689)
7. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545-51. (Pubitemid 46955114)
8. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89. (Pubitemid 46622045)
9. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010;28:2660-7.
10. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463-72.
11. Smith SC, Baras AS, Dancik G, RuY, Ding KF, Moskaluk CA, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12:137-43.
12. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, et al. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010;16:2131-7.
13. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009;181:1894-900.
14. Yutkin V, Pode D, Pikarsky E, Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol 2007;178:2660-4. (Pubitemid 350052144)
15. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol 2009;55:1386-95.
16. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18:3377-86.
17. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 2012;7:e38863.
18. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-11. (Pubitemid 34920572)
19. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classi fication of tumors using gene expression data. J Am Stat Assoc 2002;97:10.
20. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-54. (Pubitemid 34013984)
21. Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, Iozzo RV, et al. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 2006;66:7103-10. (Pubitemid 44197687)
22. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982;297:474-8. (Pubitemid 12007526)
23. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007;6:277-85. (Pubitemid 46206692)
24. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 2012;33:1843-53.
25. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010;16:2518-28.
26. Nimeus-Malmstrom E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, Amini RM, et al. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer 2010;127:961-7.
27. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006;66:2153-61.
28. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 2009;69:3501-9.
29. Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011;71:4329-33.
30. Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, et al. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer 2012;106:1177-86.
31. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34. (Pubitemid 37328884)
32. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010;362:1909-19.